Stocks
Mutual Funds
ETFs
Pro Tools
Terminal
WealthView
Pricing
Learn More
stocks544759-BOM
statements
544759-BOM

Goldline Pharmaceutical Ltd.

BSE: 544759
SME
Sector: Healthcare
Industry: Pharmaceuticals
30.10+0.1 (+0.40%)
23 Oct, 12:00 AM

Income Statement

Abridged
Understanding Income Statement
Goldline Pharmaceutical Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.
2023
Mar 31
2024
Mar 31
2025
Mar 31
2026
Mar 31
Period length:
Source:
12M
PR
12M
PR
12M
PR
12M
AR
Total Revenue
19.8523.5728.0631.20
Cost of Operating Revenue
6.006.2411.0511.43
Gross Profit
13.8417.3317.0019.77
Gross Margin
69.873.560.663.4
Total Operating Expenses
17.6319.3922.3824.50
Operating Profit
2.224.185.676.70
Operating Margin
11.217.720.221.5
Financing Income/(Expense) - Net
-1.62-1.61-1.72-1.31
Profit before Taxes
0.402.523.865.39
Income Taxes
0.140.721.021.27
Profit after Tax
0.261.802.834.12
PAT Margin
1.37.710.113.2
EPS - Basic - ex Extraordinary Items
0.271.882.954.29
EPS - Diluted - ex Extraordinary Items
0.271.882.954.29
EBIT
2.224.185.676.70
EBITDA
2.404.345.926.94
EBITDA Margin
12.118.421.122.2

Balance Sheet

Abridged
Understanding Balance Sheet
Goldline Pharmaceutical Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.
2023
Mar 31
2024
Mar 31
R
2025
Mar 31
2026
Mar 31
Source:
PR
PR
AR
AR
Total Current Assets
16.8219.5023.2626.05
Long-Term Investments
0.070.030.030.03
Property Plant & Equipment - Net
2.473.362.842.65
Total Non-Current Assets
2.573.432.932.82
Total Assets
19.3922.9326.1928.87
Total Current Liabilities
9.0010.1711.7712.11
Long Term Debt
3.814.053.191.46
Total Non-Current Liabilities
4.504.904.162.51
Total Liabilities
13.5015.0715.9314.62
Total Shareholders' Equity
5.897.8610.2614.25
Total Equity
5.897.8610.2614.25
Total Liabilities & Equity
19.3922.9326.1928.87

Cash Flow

Abridged
Understanding Cash Flow Statement
Goldline Pharmaceutical Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.
2023
Mar 31
2024
Mar 31
2025
Mar 31
2026
Mar 31
Period length:
Source:
12M
PR
12M
PR
12M
PR
12M
AR
Operating CF bef Changes in Working Cap
0.752.543.284.65
Working Capital - Increase/(Decrease)
0.03-1.23-2.69-3.15
Net CF from Operating Activities
0.771.310.601.50
Capital Expenditures - Net
1.011.11-0.170.06
Net CF from Investing Activities
-1.03-1.110.16-0.06
Dividends Paid - Cash - Total
0.220.220.210.22
Stock - Issuance/(Retirement) - Net
-0.30--
Debt - LT & ST - Issuance/(Retirement) - Total
0.390.30-0.10-1.87
Net Cash Flow from Financing Activities
0.170.53-0.31-2.09
Free Cash Flow to Equity
0.150.500.67-0.43
Free Operating CF net dividend
-0.55-0.020.181.23
Free Operating CF
-0.330.200.391.44

Business Segment Analysis

FY End:
Mar 26

Goldline Pharmaceutical Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex
Total₹ 0Cr
Pharmaceutical products (100.0%)₹ 0.06 Cr
Revenue / Sales
Total₹ 31Cr
Pharmaceutical products (100.0%)₹ 31.20 Cr
Assets
Total₹ 29Cr
Pharmaceutical products (100.0%)₹ 28.87 Cr
Operating Income
Total₹ 7Cr
Pharmaceutical products (100.0%)₹ 6.70 Cr

Regional Segment Analysis

Goldline Pharmaceutical Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Goldline Pharmaceutical Ltd.

Historical Segment Analysis

Track how Goldline Pharmaceutical Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Business
2026
Mar 31
Pharmaceutical products0

Frequently Asked Questions

What is the revenue of Goldline Pharmaceutical Ltd.?
The latest trailing twelve month revenue of Goldline Pharmaceutical Ltd. is ₹ 31.20 Cr, reflecting a 1-year growth of 11.20% and a 3-year CAGR of 16.27%. Annual and quarterly revenue trends are available in the Income Statement section.
What is the net profit of Goldline Pharmaceutical Ltd.?
The latest trailing twelve month net profit (PAT) of Goldline Pharmaceutical Ltd. is ₹ 4.12 Cr, with a 3-year earnings CAGR of 152.22%. Detailed profit history across annual and quarterly periods is in the Income Statement section.
What is the EBITDA of Goldline Pharmaceutical Ltd.?
The trailing twelve month EBITDA of Goldline Pharmaceutical Ltd. is approximately ₹ 6.70 Cr (based on an operating margin of 21.47%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.
What is the EPS of Goldline Pharmaceutical Ltd.?
The trailing twelve month Earnings Per Share (EPS) of Goldline Pharmaceutical Ltd. is 4.29. EPS trends across annual and quarterly periods are visible in the Income Statement section.
What is the debt level of Goldline Pharmaceutical Ltd.?
The debt-to-equity ratio of Goldline Pharmaceutical Ltd. stands at 0.64. The interest coverage ratio is 5.10x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.
What is the book value per share of Goldline Pharmaceutical Ltd.?
The estimated book value per share of Goldline Pharmaceutical Ltd. is 14.84 (derived from a P/B ratio of 2.03 and market price of ₹ 30.10), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.
What is the cash flow from operations of Goldline Pharmaceutical Ltd.?
The trailing twelve month operating cash flow of Goldline Pharmaceutical Ltd. is ₹ 1.50 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.
Does Goldline Pharmaceutical Ltd. report consolidated or standalone financials?
Goldline Pharmaceutical Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.